Predictive Oncology Inc. (POAI): חובות להיוון בספרים

Driven by demand for AI-driven pharma and FDA support, Predictive Oncology (POAI) retains partners through cell-based test simulations. Its proprietary bioinformatics environment creates a network effect powered by a database of tumor reactions. Historical debt-to-book value dynamics confirm financial stability, where 0.00 captures the current state of the parameter. Revenue is based on analytics licensing and conducting research for the development of personalized cancer treatments.

Predictive Oncology monetizes its AI platform through B2B subscriptions to optimize the development of anti-tumor drugs. This indicator compares total liabilities to the book value of equity to determine the degree of financial leverage. Analyzing the value of debt relative to book capitalization allows for an assessment of insolvency risk under high debt loads. A declining curve confirms increasing business autonomy and resilience to external shocks. Conservative investors interpret a low ratio as a guarantee of the issuer's solvency.